Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-10
2006-10-10
Maier, Leigh C. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07119074
ABSTRACT:
The present invention provides amphiphilic prodrugs comprising a therapeutic compound conjugated to an PEG-oligomer/polymer and methods for using said prodrugs to enable oral drug delivery and/or delivery of drugs across the blood brain barrier into the central nervous system.
REFERENCES:
patent: 4567253 (1986-01-01), Durst et al.
patent: 4636505 (1987-01-01), Tucker
patent: 5122614 (1992-06-01), Zalipsky
patent: 5219564 (1993-06-01), Zalipsky et al.
patent: 5298643 (1994-03-01), Greenwald
patent: 5321095 (1994-06-01), Greenwald
patent: 5324844 (1994-06-01), Zalipsky
patent: 5349001 (1994-09-01), Greenwald et al.
patent: 5405877 (1995-04-01), Greenwald et al.
patent: 5407683 (1995-04-01), Shively
patent: 5422364 (1995-06-01), Nicolaou et al.
patent: 5439686 (1995-08-01), Desai et al.
patent: 5455027 (1995-10-01), Zalipsky et al.
patent: 5484809 (1996-01-01), Hostetler et al.
patent: 5547981 (1996-08-01), Greenwald et al.
patent: 5560933 (1996-10-01), Soon-Shiong et al.
patent: 5567422 (1996-10-01), Greenwald
patent: 5605976 (1997-02-01), Martinez et al.
patent: 5608087 (1997-03-01), Nicolaou et al.
patent: 5612460 (1997-03-01), Zalipsky
patent: 5614549 (1997-03-01), Greenwald et al.
patent: 5618528 (1997-04-01), Cooper et al.
patent: 5622986 (1997-04-01), Greenwald et al.
patent: 5637749 (1997-06-01), Greenwald
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5681567 (1997-10-01), Martinez et al.
patent: 5681811 (1997-10-01), Ekwuribe
patent: 5730990 (1998-03-01), Greenwald et al.
patent: 5744592 (1998-04-01), Hostetler et al.
patent: 5756593 (1998-05-01), Martinez et al.
patent: 5795909 (1998-08-01), Shashoua et al.
patent: 5808096 (1998-09-01), Zalipsky
patent: 5817321 (1998-10-01), Alakhov et al.
patent: 5817840 (1998-10-01), Nicolaou et al.
patent: 5824701 (1998-10-01), Greenwald et al.
patent: 5840900 (1998-11-01), Greenwald et al.
patent: 5880131 (1999-03-01), Greenwald et al.
patent: 5902588 (1999-05-01), Greenwald et al.
patent: 5919455 (1999-07-01), Greenwald et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5965119 (1999-10-01), Greenwald et al.
patent: 5965566 (1999-10-01), Greenwald et al.
patent: 6011042 (2000-01-01), Greenwald et al.
patent: 6111107 (2000-08-01), Greenwald et al.
patent: 6113906 (2000-09-01), Greenwald et al.
patent: 6127355 (2000-10-01), Greenwald et al.
patent: 6153655 (2000-11-01), Martinez et al.
patent: 6177087 (2001-01-01), Greenwald et al.
patent: 6180095 (2001-01-01), Greenwald et al.
patent: 6194580 (2001-02-01), Greenwald et al.
patent: 6309633 (2001-10-01), Ekwuribe
patent: 6310039 (2001-10-01), Kratz
patent: 6380405 (2002-04-01), Ekwuribe
patent: 6541508 (2003-04-01), Ekwuribe
patent: 6703381 (2004-03-01), Ekwuribe
patent: 6713454 (2004-03-01), Ekwuribe
patent: 0 423 747 (1990-10-01), None
patent: 0 895 784 (1999-02-01), None
patent: P9600612 (1996-09-01), None
patent: 07082291 (1995-03-01), None
patent: WO93/24476 (1993-12-01), None
patent: WO 94/04484 (1994-03-01), None
patent: WO 94/12463 (1994-06-01), None
patent: WO94/20453 (1994-09-01), None
patent: WO 96/23794 (1996-08-01), None
patent: WO 97/33552 (1997-09-01), None
patent: WO 98/07713 (1998-02-01), None
patent: WO 98/10651 (1998-03-01), None
patent: WO 98/58927 (1998-12-01), None
patent: WO 99/30727 (1999-06-01), None
patent: WO99/48536 (1999-09-01), None
patent: WO 00/09073 (2000-02-01), None
patent: WO 00/64486 (2000-11-01), None
patent: WO 00/78302 (2000-12-01), None
patent: WO01/13957 (2001-03-01), None
patent: WO 01/19406 (2001-03-01), None
patent: WO 01/19407 (2001-03-01), None
Greenwald et al., “Drug Delivery of Anticancer Agents: Water Soluble 4-Poly (Ethylene Glycol) Derivatives of the Lignan, Podophyllotoxin,”Journal of Controlled Release, 61:281-294 (1999).
International Search Report corresponding to International Application No. PCT/US 00/24520; Date of mailing: Jul. 31, 2001.
U.S. Appl. No. 60/153,649, entitled “Amphiphilic Prodrugs,” filed Sep. 13, 1999.
U.S. Appl. No. 60/153,579, entitled “Taxane Prodrugs,” filed Sep. 13, 1999.
U.S. Appl. No. 10/018,879, entitled “Amphiphilic Insulin-Oligomer Conjugates with Hydrolyzable Lipophile Components,” filed Aug. 5, 2002.
International Search Report Corresponding to International Application No. PCT/US 00/24523; Date of Mailing: Aug. 6, 2001.
U.S. Appl. No. 10/774,903, entitled “Amphiphilic Drug-Oligomer Conjugates with Hydrolyzable Lipophile Components and Methods for Making and Using the Same” filed Feb. 9, 2004.
U.S. Appl. No. 10/811, 760, entitled “Drug-Oligomer Conjugates” filed Mar. 29, 2004.
U.S. Appl. No. 10/395,548, entitled “Taxane Prodrugs” filed Mar. 24, 2003.
U.S. Appl. No. 09/429,798, entitled “Blood-Brain Barrier Therapeutics” filed Oct. 29, 1999.
U.S. Appl. No. 09/430,735, entitled “Methods of Inducing Analgesia” filed Oct. 29, 1999.
U.S. Appl. No. 10/716,975, entitled “Methods of Activating Receptor Using Amphiphilic Drug-Oligomer Conjugates” filed Nov. 19, 2003.
U.S. Appl. No. 10/716,578, entitled “Methods of Altering the Binding Affinity of a Peptide to its Receptor” filed Nov. 11, 2003.
Adams, Jonathan D., et al. “Taxol: A History of Pharmaceutical Development and Current Pharmaceutical Concerns.” J. Natl Cancer Inst Monographs (1993) 15: 141-147.
Arbuck, S.G. “Taxol (paclitaxel): Future directions.” Annals of Oncology (1994) 5(Suppl 6): S59-S62.
Beijnen, Jos H., et al. “Bioanalysis, Pharmacokinetics, and Pharmacodynamics of the Novel Anticancer Drug Paclitaxel (Taxol).” Sem in Oncology (1994) 21 (5) (Suppl Oct. 8) 53-62.
Deutsch, H.M., et al. “Synthesis of Congeners and Prodrugs. 3.1Water-Soluble Prodrugs of Taxol with Potent Antitumor Activity.” J Medicinal Chem (1989) 32: 788-792.
Greenwald, R.B., et al. “Drug Delivery Systems: Water Soluble Taxol 2′-Poly(ethylene) glycol) Ester Prodrugs—Design andin VivoEffectiveness.” J. Medicinal Chem (1996) 39:424-431.
Greenwald, R.B. et al. “Highly Water Soluble Taxol Derivatives: 7-Polyethylene Glycol Carbamates and Carbonates.” J Org Chem (1995) 60: 331-336.
Horwitz, S.B. “TAXOL (paclitaxel): Mechanisms of action.” Annals of Oncology (1994) 5 (Suppl.6): S3-S6.
Kingston, David G.I. “Taxol: the chemistry and structure-activity relationships of a novel anticancer agent.” TIBTECH (Jun. 1994) 12: 222-227.
Kingston, David G.I. “The chemistry of Taxol.” Pharmac Ther (1991) 52: 1-33.
Kohler, David R., et al. “Paclitaxel (Taxol).” (1994) Pharmacotherapy 14 (1): 3-34.
Long, Harry J. “Paclitaxel (Taxol): A Novel Anticancer Chemotherapeutic Drug.” Mayo Clin Proc (1994) 69: 341-345.
Parekh, H. et al. “The Transport and Binding of Taxol.” Gen Pharmac (1997) 29 (2): 167-172.
Preston, N.J. “Paclitaxel (Taxol)—a guide to administration.” European J of Cancer Care (1996) 5: 147-152.
Rowinsky, Eric K. et al. “The Clinical Pharmacology and Use of Antimicrotubule Agents in Cancer Chemotherapeutics.” Pharmac Ther (1991) 52: 35-84.
Rowinsky, Eric K. et al. “Taxol: The First of the Taxanes, an Important New Class of Antitumor Agents.” Seminars in Oncology (Dec. 1992) 19(6): 646-662.
Rowinsky, Eric K. et al. “Taxol: Pharmacology, Metabolism and Clinical Implications.” Cancer Surveys (1993) 17: 283-304.
Straubinger, Robert M. et al. “Novel Taxol Formulations: Taxol-Containing Liposomes.” J Nat Cancer Inst Monographs (1993) No. 15: 69-78.
Workman, Paul. “Pharmacokinetics and Cancer: Successes, Failures and Future Prospects.” Cancer Surveys (1993) 17: 1-26.
Delgado et al. “The Uses and Properties of PEG-Linked Proteins”.Critical Review in Therapeutic Drug Carrier Systems, 9(3, 4):249-304 (1992).
Doyle et al. “Second generation analogs of etoposide and mitomycin C.”Cancer Treatment Reviews(1990) 17, 127-131.
Abstract. Spige
Dyakonov Tatyana A.
Ekwuribe Nnochiri
Price Christopher H.
Barrett William A.
Maier Leigh C.
Moore & Van Allen PLLC
Nobex Corporation
LandOfFree
Treatment of cancers, tumors and malignancies using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of cancers, tumors and malignancies using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cancers, tumors and malignancies using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3621713